Tests brain stimulation on thinking and brain function in schizophrenia
Tests magnetic stimulation of the cerebellum in adults with schizophrenia, compared with a fake treatment.
Plain-language title generated from the registry record
Registry title: Impact of Cerebellar TMS on Brain and Cognitive Functions in Schizophrenia: a Pilot Study
Key facts
- Where
- New York, United StatesSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 60 years old?
Source: NCT05389787, who can take part
Where in United States
- Zucker Hillside HospitalNew York, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Northwell Health
- Trial code
- NCT05389787
- Record updated
- 28 October 2026
- Original description
This is a single-site, sham-controlled, randomized trial in a total of 40 subjects between ages 18 and 60 years with schizophrenia. This study will investigate the effects of 4-week rTMS treatment on brain and cognitive functions in patients. Subjects will be randomized to one of the following arms:Read full original descriptionShow less
Impact of Cerebellar TMS on Brain and Cognitive Functions in Schizophrenia: a Pilot Study
This is a single-site, sham-controlled, randomized trial in a total of 40 subjects between ages 18 and 60 years with schizophrenia. This study will investigate the effects of 4-week rTMS treatment on brain and cognitive functions in patients. Subjects will be randomized to one of the following arms:
Arm 1: Standard of Care (SOC) and active rTMS Arm 2: Standard of Care (SOC) and sham rTMS
Each participant will receive rTMS five days per week, for four consecutive weeks. Functional magnetic resonance imaging (fMRI) scans, clinical assessments, and cognitive tests will be performed at baseline, end of the 2nd week, and end of the 4th week.
Inclusion: Male or female subjects 18 to 60 years of age; DSM-V diagnosis of schizophrenia spectrum disorders; Competent to provide informed consent.
Exclusion: Lifetime DSM-V diagnosis of an Axis-I disorder other than schizophrenia spectrum disorders; Lifetime diagnosis of ataxia or other cerebellar disorders; Lifetime diagnosis of mental retardation, dementia, Alzheimer's disease, Parkinson's disease, Huntington's disease, or other neurodegenerative disorders; Any active general medical condition or CNS disease which can affect cognition or response to treatment; Seizure history; Substance dependence or abuse in the past six months; TMS within three months or ECT within six months; Pregnancy as indicated by self-report; MRI contraindications.